Surrogate end points in the design of immunotherapy trials: Emerging lessons from type 1 diabetes

Nature Reviews Immunology

Volumn 10, Issue 2, 2010, Pages 145-152

  Roep, Bart O ^a   Peakman, Mark ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b and University of Bristol   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CANAKINUMAB; CYCLOSPORIN; DACLIZUMAB; DIAPEP277; DNA VACCINE; GLUTAMATE DECARBOXYLASE 65; INSULIN; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OTELIXIZUMAB; PROINSULIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TEPLIZUMAB; THYMOCYTE ANTIBODY; TOLERX; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; AUTOIMMUNE DISEASE; CLINICAL TRIAL; DEVELOPED COUNTRY; DISEASE MARKER; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HEALTH CARE POLICY; HUMAN; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PATHOGENESIS; PRIORITY JOURNAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOTHERAPY; RESEARCH DESIGN;

EID: 75649134941     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2705     Document Type: Note

References (71)

1. Descotes, J. Immunotoxicology: role in the safety assessment of drugs. Drug Saf. 28, 127-136 (2005).
2. Mandrup-Poulsen, T. et al. Disappearance and reappearance of islet cell cytoplasmic antibodies in cyclosporin-treated insulin-dependent diabetics. Lancet 1, 599-602 (1985).
3. Heidt, S. et al. Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin. Exp. Immunol. 18 Nov 2009 (doi:10.1111/j.1365-2249.2009.04051.x).
4. Huurman, V. A. et al. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. Clin. Exp. Immunol. 152, 488-497 (2008).
5. Roep, B. O. et al. Auto-and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes 48, 484-490 (1999).
6. Bougneres, P. F. et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 39, 1264-1272 (1990).
7. Herold, K. C. et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692-1698 (2002).
8. Keymeulen, B. et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352, 2598-2608 (2005). (Pubitemid 41007846)
9. Cernea, S. & Herold, K. C. Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies. Clin. Immunol. 16 Oct 2009 (doi:10.1016/j.clim.2009.09.005).
10. Herold, K. C. et al. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala). J. Clin. Invest. 111, 409-418 (2003).
11. + Tregs. J. Clin. Invest. 11 5, 2904-2913 (2005).
12. Pescovitz, M. D. et al. Rituximab, B-lymphocyte depletion, and preservation of β-cell function. N. Engl. J. Med. 361, 2143-2152 (2009).
13. Ludvigsson, J. et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N. Engl. J. Med. 359, 1909-1920 (2008).
14. Staeva-Vieira, T., Peakman, M. & von Herrath, M. Translational mini-review series on type 1 diabetes: immune-based therapeutic approaches for type 1 diabetes. Clin. Exp. Immunol. 148, 17-31 (2007). (Pubitemid 46364996)
15. Peakman, M. et al. Characterization of preparations of GAD65, proinsulin, and the islet tyrosine phosphatase IA-2 for use in detection of autoreactive T-cells in type 1 diabetes: report of phase II of the Second International Immunology of Diabetes Society Workshop for Standardization of T-cell assays in type 1 diabetes. Diabetes 50, 1749-1754 (2001).
16. Roep, B. O. et al. Autoreactive T cell responses in insulin-dependent (type 1) diabetes mellitus. Report of the first international workshop for standardization of T cell assays. J. Autoimmun. 13, 267-282 (1999).
17. Babel, N., Reinke, P. & Volk, H. D. Lymphocyte markers and prediction of long-term renal allograft acceptance. Curr. Opin. Nephrol. Hypertens. 18, 489-494 (2009).
18. Seyfert-Margolis, V. et al. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes 55, 2588-2594 (2006).
19. Schloot, N. C. et al. Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology of diabetes society T-cell workshop. J. Autoimmun. 21, 365-376 (2003).
20. Janetzki, S. et al. "MIATA" -minimal information about T cell assays. Immunity 31, 527-528 (2009).
21. Herold, K. C. et al. Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes 58, 2588-2595 (2009).
22. Weis, J. H. Allergy test might have avoided drug-trial disaster. Nature 441, 150 (2006).
23. Bresson, D. et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest. 11 6, 1371-1381 (2006).
24. Valle, A. et al. Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice. Diabetes 58, 875-881 (2009).
25. Hayday, A. C. & Peakman, M. The habitual, diverse and surmountable obstacles to human immunology research. Nature Immunol. 9, 575-580 (2008).
26. Arechiga, A. F. et al. Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J. Immunol. 182, 3343-3347 (2009).
27. Dendrou, C. A. et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nature Genet. 41, 1011-1015 (2009).
28. Tabrizi, M. A. & Roskos, L. K. Preclinical and clinical safety of monoclonal antibodies. Drug Discov. Today 12, 540-547 (2007).
29. Stebbings, R. et al. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J. Immunol. 179, 3325-3331 (2007).
30. Thrower, S. L. et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man phase I safety study. Clin. Exp. Immunol. 155, 156-165 (2009).
31. Roep, B. O., Atkinson, M. & von Herrath, M. Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nature Rev. Immunol. 4, 989-997 (2004).
32. van de Linde, P. et al. Mechanisms of antibody immunotherapy on clonal islet reactive T cells. Hum. Immunol. 67, 264-273 (2006).
33. null) null mice: a radioresistant model for human lymphohaematopoietic engraftment. Clin. Exp. Immunol. 154, 270-284 (2008).
34. Shultz, L. D., Ishikawa, F. & Greiner, D. L. Humanized mice in translational biomedical research. Nature Rev. Immunol. 7, 118-130 (2007).
35. Nicoletti, F. et al. Serum concentrations of the interferon-γ- inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 45, 1107-1110 (2002).
36. Pfleger, C. et al. Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes. Clin. Immunol. 128, 57-65 (2008).
37. Pfleger, C. et al. Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes. Diabetes 57, 929-937 (2008).
38. Lai, Y., Chen, C. & Linn, T. Innate immunity and heat shock response in islet transplantation. Clin. Exp. Immunol. 157, 1-8 (2009).
39. Padmos, R. C. et al. Distinct monocyte gene-expression profiles in autoimmune diabetes. Diabetes 57, 2768-2773 (2008).
40. Allen, J. S. et al. Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes 58, 138-145 (2009).
41. Beyan, H. et al. Altered monocyte cyclo-oxygenase response in non-obese diabetic mice. Clin. Exp. Immunol. 155, 304-310 (2009).
42. Arif, S. et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 113, 451-463 (2004).
43. Voltarelli, J. C. et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 297, 1568-1576 (2007).
44. Simon, G. et al. Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation. Diabetes 57, 405-414 (2008).
45. hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin. Exp. Immunol. 154, 353-359 (2008).
46. + T-cells from patients with type 1 diabetes. Diabetes 54, 92-99 (2005).
47. + regulatory T cells. J. Immunol. 181, 7350-7355 (2008).
48. + T cell epitopes in human type 1 diabetes. Clin. Exp. Immunol. 156, 226-231 (2009).
49. Spencer, J. & Peakman, M. Post-mortem analysis of islet pathology in type 1 diabetes illuminates the life and death of the β cell. Clin. Exp. Immunol. 155, 125-127 (2009).
50. Planas, R. et al. Gene expression profiles for the human pancreas and purified islets in type 1 diabetes: new findings at clinical onset and in long-standing diabetes. Clin. Exp. Immunol. 159, 23-44 (2009).
51. Hu, C., Wong, F. S. & Wen, L. Translational mini-review series on B cell-directed therapies: B cell-directed therapy for autoimmune diseases. Clin. Exp. Immunol. 157, 181-190 (2009).
52. Crome, S. Q., Wang, A. Y. & Levings, M. K. Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clin. Exp. Immunol. 11 Nov 2009 (doi:10.1111/j.1365-2249. 2009.04037.x).
53. Koenders, M. I. & van den Berg, W. B. Translational mini-review series on Th17 cells: are T helper 17 cells really pathogenic in autoimmunity? Clin. Exp. Immunol. 11 Nov 2009 (doi:10.1111/j.1365-2249.2009.04039.x).
54. Pinkse, G. G. et al. Autoreactive CD8 T cells associated with β cell destruction in type 1 diabetes. Proc. Natl Acad. Sci. USA 102, 18425-18430 (2005).
55. Skowera, A. et al. CTLs are targeted to kill β cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J. Clin. Invest. 11 8, 3390-3402 (2008).
56. Monti, P. et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J. Clin. Invest. 11 8, 1806-1814 (2008).
57. Willcox, A., Richardson, S. J., Bone, A. J., Foulis, A. K. & Morgan, N. G. Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol. 155, 173-181 (2009).
58. Bougneres, P. F. et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N. Engl. J. Med. 318, 663-670 (1988).
59. Martin, S. et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N. Engl. J. Med. 345, 1036-1040 (2001).
60. Huurman, V. A. et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS ONE 3, e2435 (2008).
61. Hilbrands, R. et al. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes 58, 2267-2276 (2009).
62. Bingley, P. J. et al. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 43, 1304-1310 (1994).
63. Verge, C. F. et al. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes 47, 1857-1866 (1998).
64. Verge, C. F. et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 45, 926-933 (1996).
65. Brusko, T. M., Putnam, A. L. & Bluestone, J. A. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol. Rev. 223, 371-390 (2008).
66. Gregori, S., Battaglia, M. & Roncarolo, M. G. Re-establishing immune tolerance in type 1 diabetes via regulatory T cells. Novartis Found. Symp. 292, 174-183 (2008).
67. + cells at diagnosis predict glycaemic control in type 1 diabetes. Clin. Immunol. 127, 138-143 (2008)
68. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N. Engl. J. Med. 346, 1685-1691 (2002).
69. Skyler, J. S. et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial -Type 1. Diabetes Care 28, 1068-1076 (2005).
70. Harrison, L. C. et al. Pancreatic β-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 27, 2348-2355 (2004).
71. Pfleger, C., Meierhoff, G., Kolb, H. & Schloot, N. C. Association of T-cell reactivity with β-cell function in recent onset type 1 diabetes patients. J. Autoimmun. 9 Sep 2009 (doi:10.1016/j.jaut.2009.08.004).